Análisis Argos
ERAS
ERASSin veredicto1 señal de riesgo
Erasca, Inc. · Healthcare
US$ 18.47
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
15/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
Tiene más caja que deuda: balance fuerte.
Riesgos
!Crecimiento estancado o en baja.
!Altman Z'' en zona roja (-0.49)
VALOR1/6FUTURO2/6PASADO0/6SALUD0/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO2/6PASADO0/6SALUD0/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial débil
SaludBalance frágil
DividendoEl dividendo aún duerme
Score Argos15de 100Sin veredicto
Ingresos
Margen operativo
Flujo de caja libre23%
US$ -0.1 B
Deuda neta
US$ -0 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 5.7B
P/E
EV/EBITDA
FCF yield-1.7%
ROIC-44%
Margen operativo
Crecim. ingresos
Piotroski F4/9
Novedades

Noticias recientes

newsfilecorp.com · 4 jul
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS
New York, New York--(Newsfile Corp. - July 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline. SO WHAT: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
gurufocus.com · 3 jul
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick and Foti, LLC, Befo
prnewswire.com · 3 jul
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
NEW YORK and NEW ORLEANS, July 3, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. ("Erasca" or the "Company") (NasdaqGS: ERAS) of a class action securities lawsuit.
businesswire.com · 3 jul
ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.Investors have until August 10, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The le.
globenewswire.com · 3 jul
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS
NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline.
globenewswire.com · 3 jul
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca's pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015. The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026.
globenewswire.com · 3 jul
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, July 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. (“Erasca” or “the Company”) (NASDAQ: ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before August 10, 2026.
prnewswire.com · 2 jul
ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 2, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.